CD47 and neoplasm: On the one hand, antibodies targeting CD47 or SIRPα, recombinant SIRPα, or TSP1-derived proteins promote phagocytosis and tumor cell elimination by disrupting the CD47–SIRPα interaction and/or inducing Fc-dependent mechanisms or PCD [15,17–28].